Thus, these observations indicate that circulating Galectin-3 may serve as a promising biomarker for T1D risk stratification, and the Galectin-3 inhibitor may offer an immunoregulatory avenue for preventing T1D in high-risk individuals with elevated Galectin-3 levels. This evidence concerns the gene LGALS3 and type 1 diabetes mellitus.